ALFA Finder
10:37 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sandu Pharmaceuticals Ltd
- Share price
- ₹37.68
- Market cap
- ₹36.40 Cr
- Revenue (annual)
- ₹69.93 Cr
- Net profit (annual)
- ₹1.77 Cr
- P/E (TTM)
- 15.0×Sector 43.8×
- Promoter holding
- 37.79%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
All
Other Announcement 7Board Meeting Date 3Management Change 2Annual General Meeting 2Financial Results 1Annual Report 1
Time
7 announcements with these filters
11:40 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals intimated that Non-Executive Independent Director Dr Neeti Madan Kapre has changed her name to Dr Neeti Gupta after marriage. The DIN, designation and directorship remain unchanged.
12:18 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Limited has issued a reminder to physical shareholders regarding the mandatory submission of PAN and KYC details. This compliance follow-up aims to facilitate electronic dividend payments.
15:14 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
17:41 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Ltd issued a letter to shareholders whose email addresses are not registered, providing the weblink to the Annual Report for FY 2026-27.
18:38 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals Limited filed its quarterly Statement of Deviation or Variation in utilization of funds for the quarter ended June 30, 2026. No deviation or variation was reported.
10:52 IST
BSE
Other Announcement
Sandu Pharmaceuticals Other Announcement
Sandu Pharmaceuticals filed its Annual Secretarial Compliance Report for the year ended March 2026. The auditor confirmed general regulatory compliance with minor previous reporting delays noted.